Sandoz launches Pyzchiva autoinjector in Europe
Sandoz announced the European launch of its Pyzchiva (ustekinumab) autoinjector. This is the first ustekinumab biosimilar in Europe commercially available in an autoinjector.
Developed and registered by Samsung Bioepis, Pyzchiva is approved for the treatment of adults with plaque psoriasis, psoriatic arthritis, Crohn’s disease and pediatric plaque psoriasis for patients aged six years and older, weighing more than 60 kg.
Pyzchiva is a biosimilar to Johnson & Johnson’s Stelara.
[Read more: AAM: IRA hampers generic, biosimilar drug competition]
Sandoz said the Pyzchiva autoinjector supports a more comfortable self-administration experience with accurate automatic dosing, less frequent injection pain, a compact design and flexible storage options offering the potential for improved adherence to patient treatment plans.
Christophe Delenta, president Europe at Sandoz, said, “Access to medicine does not end when it reaches the hands of the patient. The Pyzchiva autoinjector, with its thoughtful and advanced features, addresses the real-world needs of patients in managing chronic inflammatory diseases. This launch marks another important milestone as we strengthen our leadership in immunology biosimilars and reaffirm our commitment to pioneering access across Europe’s evolving healthcare landscape.”
Pyzchiva is a key biosimilar value driver for the Sandoz growth strategy. It has been launched in 23 markets in Europe. The autoinjector is now available in Spain and will continue to roll out across Europe.
[Read more: Biosimilars Forum, Biosimilars Council urge Congressional action on biosimilars]
Sandoz entered into a development and commercialization agreement for biosimilar ustekinumab with Samsung Bioepis in September 2023. Under the terms of the agreement, Sandoz has the right to commercialize Pyzchiva in Brazil, the United States, the European Economic Area, Switzerland and the United Kingdom. Samsung Bioepis remains responsible for development, registration, intellectual property, manufacturing and supply.